Three prominent examples are polatuzumab vedotin for large B cell lymphoma, brentuximab vedotin for Hodgkin lymphoma, and ado-trastuzumab emtansine for human epidermal growth factor receptor 2 (HER2)-positive breast cancer [210]. This evidence concerns the gene ERBB2 and breast cancer.